Journal
BLOOD
Volume 132, Issue 6, Pages 608-621Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2018-04-845602
Keywords
-
Categories
Funding
- Leukaemia Foundation
- Cancer Council of Victoria [APP1126010]
- National Health and Medical Research Council (NHMRC) [APP1024363/APP1102589]
- Cancer Institute of NSW Translational Cancer Research Network
- South Eastern Area Laboratory Services
- Anthony Rothe Memorial Trust
- Victorian Cancer Agency Research Fellowship [MCRF15015]
- NHMRC [APP1003339]
- UNSW International PhD scholarship
- Tom Bee Stem Cell Research Fund
- Victorian State Government OIS
Ask authors/readers for more resources
Mutations in SRSF2 occur in myelodysplastic syndromes (MDS) and MDS/myeloproliferative neoplasms (MPN). SRSF2 mutations cluster at proline 95, with the most frequent mutation being a histidine (P95H) substitution. They undergo positive selection, arise early in the course of disease, and have been identified in age-related clonal hemopoiesis. It is not clear how mutation of SRSF2 modifies hemopoiesis or contributes to the development of myeloid bias or MDS/MPN. Two prior mouse models of Srsf2(P95H) mutation have been reported; however, these models do not recapitulate many of the clinical features of SRSF2-mutant disease and relied on bone marrow (BM) transplantation stress to elicit the reported phenotypes. We describe a new conditional murine Srsf2(P95H) mutation model, where the P95H mutation is expressed physiologically and heterozygously from its endogenous locus after Cre activation. Using multiple Cre lines, we demonstrate that during native hemopoiesis (ie, no BM transplantation), the Srsf2(P95H) mutation needs to occur within the hemopoietic stem-cell-containing populations to promote myelomonocytic bias and expansion with corresponding transcriptional and RNA splicing changes. With age, nontransplanted Srsf2(P95H) animals developed a progressive, transplantable disease characterized by myeloid bias, morphological dysplasia, and monocytosis, hallmarks of MDS/MPN in humans. Analysis of cooccurring mutations within the BM demonstrated the acquisition of additional mutations that are recurrent in humans with SRSF2 mutations. The tractable Srsf2(P95H/+) knock-in model we have generated is highly relevant to human disease and will serve to elucidate the effect of SRSF2 mutations on initiation and maintenance of MDS/MPN.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available